Semaglutide May Improve Attention and Memory in Depression, But Not Mood Itself | Research

The takeaway

A placebo-controlled trial found semaglutide improved attention and memory in depressed patients, but did not significantly reduce overall depressive symptoms.

Cognition improved, mood did not
Semaglutide dissociated cognitive benefits from antidepressant effects in a placebo-controlled trial

What the researchers found

Semaglutide improved attention and memory in depressed patients without significantly improving depressive symptoms, suggesting separate cognitive and mood pathways.

Why it matters

Cognitive deficits are among the most disabling and undertreated aspects of depression. If GLP-1 drugs can address these deficits through anti-inflammatory mechanisms, they could fill a major treatment gap.

How the study worked

Commentary on a placebo-controlled trial by Badulescu et al. examining semaglutide effects on cognition and depression.

What this study cannot tell us

Brief commentary without independent data analysis. The referenced trial sample size and duration are not detailed in this piece.

How to read the evidence

Expert commentary on a single placebo-controlled trial; suggestive but preliminary evidence.

When this study was published

Published in 2026.

The bigger picture

This supports a growing view that depression-related cognitive decline and mood symptoms may have distinct biological drivers, with inflammation playing a key role in the cognitive component.

Questions still open

Can semaglutide be combined with antidepressants to address both cognitive and mood symptoms?
Which depressed patients are most likely to benefit cognitively from GLP-1 therapy—those with higher inflammation markers?

Common questions

Can semaglutide treat depression?

Not directly—this trial found no significant mood improvement. However, it did improve attention and memory, suggesting GLP-1 drugs might help the cognitive symptoms of depression through anti-inflammatory pathways.

Why would a diabetes drug help brain function in depression?

GLP-1 receptors exist in the brain, and semaglutide may reduce the low-grade systemic inflammation that contributes to cognitive impairment in depression.

Read the original research

Depression, cognition, and GLP-1 receptors: Heterogeneity and therapeutic prospects.

Med (New York, N.Y.), 7(1), 100954

View on PubMed ↗Publisher’s paper ↗

Citation

Chen, Mu-Hong; Bai, Ya-Mei; Tsai, Shih-Jen. (2026). Depression, cognition, and GLP-1 receptors: Heterogeneity and therapeutic prospects.. Med (New York, N.Y.), 7(1), 100954. https://doi.org/10.1016/j.medj.2025.100954